EGFR and non-small cell lung carcinoma: Subsequently, they analyzed the expression profile of NSCLC patients by using the EGFR signature as a probe, and found that a subset of the clinical samples showed a coherent expression pattern, indicating that the EGFR mutation signature developed with cultured cell lines could potentially predict the mutation status of clinical samples.